Rounder Acquires Rights to Its First Medical Produ
Post# of 95
Posted On: 12/21/2012 2:03:55 PM
Rounder Acquires Rights to Its First Medical Product Formulation
Dec 20, 2012 (Close-Up Media via COMTEX) -- Rounder Inc. medical division has acquired the formulation rights for a heart healthy nutraceutical product.
According to a release, roughly one-third of adults use nutraceuticals and 15 million Americans use them together with conventional medicines. A study from the Mayo clinic found that 61 percent of those 18 years of age and older had used a nutraceutical over the past year.
In addition, the company noted:
With sales of nutraceutical products increasing 25 percent per year in the United States, the US market for nutraceuticals is expected to reach $891 million in consumer purchases by 2013. Our capture of just a small percentage of market share in this rapidly growing industry segment should result in substantial revenue for the company.
Marketing and manufacturing for the newly acquired product is expected in the first quarter of 2013 following the completion of the branding process. Distribution is then expected to begin before the end of March 2013. While the company negotiates the purchase of additional products, we are actively developing strategic partners with marketing firms that have a proven record of success relating to the development of retail accounts and product distributers within the nutraceuticals market.
Our first product to enter into our Medical Products division is classified as an anti-inflammatory, as the product assists in reducing body inflammation. Chronic inflammation can have serious effects on the human body. Science has made links between chronic inflammation and various degenerative diseases including cancer, heart disease, diabetes, Alzheimer's and many others. When inflammation occurs, chemicals such as inflammatory cytokines are released into the blood or tissues. Inflammatory cytokines are destructive to our normal cells.
As mentioned the company is actively seeking additional nutraceutical products to build a dynamic product line. The products we seek will assist in reducing coronary artery blockage, reduce all types of body fat and lipid compounds, and generally increase the health of the human cardiovascular system.
In other events, the company has received approval from FINRA for our name change, "Fortitude Group Inc." We still await our new trading symbol. The company remains confident that our discussions involving the acquisition of a medical device company will conclude successfully, and we will provide further updates as they become relevant.
Dec 20, 2012 (Close-Up Media via COMTEX) -- Rounder Inc. medical division has acquired the formulation rights for a heart healthy nutraceutical product.
According to a release, roughly one-third of adults use nutraceuticals and 15 million Americans use them together with conventional medicines. A study from the Mayo clinic found that 61 percent of those 18 years of age and older had used a nutraceutical over the past year.
In addition, the company noted:
With sales of nutraceutical products increasing 25 percent per year in the United States, the US market for nutraceuticals is expected to reach $891 million in consumer purchases by 2013. Our capture of just a small percentage of market share in this rapidly growing industry segment should result in substantial revenue for the company.
Marketing and manufacturing for the newly acquired product is expected in the first quarter of 2013 following the completion of the branding process. Distribution is then expected to begin before the end of March 2013. While the company negotiates the purchase of additional products, we are actively developing strategic partners with marketing firms that have a proven record of success relating to the development of retail accounts and product distributers within the nutraceuticals market.
Our first product to enter into our Medical Products division is classified as an anti-inflammatory, as the product assists in reducing body inflammation. Chronic inflammation can have serious effects on the human body. Science has made links between chronic inflammation and various degenerative diseases including cancer, heart disease, diabetes, Alzheimer's and many others. When inflammation occurs, chemicals such as inflammatory cytokines are released into the blood or tissues. Inflammatory cytokines are destructive to our normal cells.
As mentioned the company is actively seeking additional nutraceutical products to build a dynamic product line. The products we seek will assist in reducing coronary artery blockage, reduce all types of body fat and lipid compounds, and generally increase the health of the human cardiovascular system.
In other events, the company has received approval from FINRA for our name change, "Fortitude Group Inc." We still await our new trading symbol. The company remains confident that our discussions involving the acquisition of a medical device company will conclude successfully, and we will provide further updates as they become relevant.
(0)
(0)Fortitude Group, Inc. (FRTD) Stock Research Links
Scroll down for more posts ▼